Aug. 8 (Bloomberg) -- ImClone Systems Inc., maker of the Erbitux cancer drug, agreed to pay Abbott Laboratories $17.5 million to end a patent-infringement lawsuit over the medicine.
Aug. 8 (Bloomberg) -- ImClone Systems Inc., maker of the Erbitux cancer drug, agreed to pay Abbott Laboratories $17.5 million to end a patent-infringement lawsuit over the medicine.